The Biological and Chemical Basis for Tissue-Selective Amyloid Disease

[1]  J. Sacchettini,et al.  Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization. , 2003, Journal of the American Chemical Society.

[2]  C. Wurth,et al.  The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.

[3]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[4]  F. Studier,et al.  Use of T7 RNA polymerase to direct expression of cloned genes. , 1990, Methods in enzymology.

[5]  Wei Zheng,et al.  Establishment and characterization of an immortalized Z310 choroidal epithelial cell line from murine choroid plexus , 2002, Brain Research.

[6]  J. Kelly,et al.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. , 1996, Biochemistry.

[7]  T. Tokuda,et al.  Energetic Characteristics of the New Transthyretin Variant A25T May Explain Its Atypical Central Nervous System Pathology , 2003, Laboratory Investigation.

[8]  B. Wallin,et al.  Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis , 1993, The Lancet.

[9]  K. Yutani,et al.  Folding mechanism of mutant human lysozyme C77/95A with increased secretion efficiency in yeast. , 1992, The Journal of biological chemistry.

[10]  Fred E. Cohen,et al.  Therapeutic approaches to protein-misfolding diseases , 2003, Nature.

[11]  J. Menting,et al.  Thyroxine transport in choroid plexus. , 1987, The Journal of biological chemistry.

[12]  O. Suhr,et al.  Long‐term follow‐up of survival of liver transplant recipients with familial amyloid polyneuropathy (Portuguese type) , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[13]  J. Hamilton,et al.  Transthyretin: a review from a structural perspective , 2001, Cellular and Molecular Life Sciences CMLS.

[14]  K. Sletten,et al.  Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Michel Bouvier,et al.  Pharmacological chaperones: potential treatment for conformational diseases , 2004, Trends in Endocrinology & Metabolism.

[16]  C. Der,et al.  GTP-binding mutants of rab1 and rab2 are potent inhibitors of vesicular transport from the endoplasmic reticulum to the Golgi complex , 1992, The Journal of cell biology.

[17]  A Helenius,et al.  Setting the standards: quality control in the secretory pathway. , 1999, Science.

[18]  Joleen T White,et al.  D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? , 2003, Biochemistry.

[19]  R. Webster,et al.  Assembly of influenza hemagglutinin trimers and its role in intracellular transport , 1986, The Journal of cell biology.

[20]  F. Garzuly.  [Clinical characteristics of Hungarian-type familial meningo-cerebrovascular amyloidosis]. , 1996, Orvosi hetilap.

[21]  T. Harkany,et al.  Cutaneous lymphatic amyloid deposits in ‘Hungarian‐type’ familial transthyretin amyloidosis: a case report , 2002, The British journal of dermatology.

[22]  Joleen T White,et al.  Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. , 2004, Biochemistry.

[23]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[24]  J. Kelly,et al.  Alternative conformations of amyloidogenic proteins govern their behavior. , 1996, Current opinion in structural biology.

[25]  M. Kikuchi,et al.  Behavior of cysteine mutants of human lysozyme in de novo synthesis and in vivo secretion. , 1991, European journal of biochemistry.

[26]  J. Riordan,et al.  COPII-dependent export of cystic fibrosis transmembrane conductance regulator from the ER uses a di-acidic exit code , 2004, The Journal of cell biology.

[27]  Daniel R. Jacobson,et al.  Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement , 1992, Human Genetics.

[28]  Scott A. Peterson,et al.  Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Benson.  Leptomeningeal amyloid and variant transthyretins. , 1996, The American journal of pathology.

[30]  J. Kearney,et al.  Posttranslational association of immunoglobulin heavy chain binding protein with nascent heavy chains in nonsecreting and secreting hybridomas , 1986, The Journal of cell biology.

[31]  C. Dobson.  Protein folding and misfolding , 2003, Nature.

[32]  S. Gottesman,et al.  Posttranslational quality control: folding, refolding, and degrading proteins. , 1999, Science.

[33]  C. Lacroix,et al.  Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy , 1998, Neurology.

[34]  K. Mori.  Tripartite Management of Unfolded Proteins in the Endoplasmic Reticulum , 2000, Cell.

[35]  Ernest Beutler,et al.  Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Benson,et al.  Polymorphism of human plasma thyroxine binding prealbumin. , 1983, Biochemical and biophysical research communications.

[37]  M. Benson,et al.  Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. , 1986, The Journal of clinical investigation.

[38]  M. Nakazato,et al.  Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. , 1995, Biochemical and biophysical research communications.

[39]  S. Ikeda.  Clinical Picture and Outcome of Transthyretin-Related Familial Amyloid Polyneuropathy (FAP) in Japanese Patients , 2002, Clinical chemistry and laboratory medicine.

[40]  F. Spagnoli,et al.  Identification of a Bipotential Precursor Cell in Hepatic Cell Lines Derived from Transgenic Mice Expressing Cyto-Met in the Liver , 1998, The Journal of cell biology.

[41]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[42]  J. Kelly,et al.  Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.

[43]  H. Budka,et al.  Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly) , 1996, Neurology.

[44]  Jian‐Qiang Fan.  A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. , 2003, Trends in pharmacological sciences.

[45]  K D Wittrup,et al.  Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. , 1999, Journal of molecular biology.

[46]  H. M. Petrassi,et al.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. , 2001, Biochemistry.

[47]  R. Schekman,et al.  Bi-directional protein transport between the ER and Golgi. , 2004, Annual review of cell and developmental biology.

[48]  W. Balch,et al.  Mise en place-this bud's for the Golgi. , 2004, Molecular cell.

[49]  M. Benson,et al.  Primary structure of an amyloid prealbumin and its plasma precursor in a heredofamilial polyneuropathy of Swedish origin. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Kopito,et al.  Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism. , 2003, Methods in molecular biology.

[51]  K D Wittrup,et al.  Secretion efficiency in Saccharomyces cerevisiae of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. , 1998, Biochemistry.

[52]  K D Wittrup,et al.  Protein Folding Stability Can Determine the Efficiency of Escape from Endoplasmic Reticulum Quality Control* , 1998, The Journal of Biological Chemistry.

[53]  B. Moss,et al.  Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Goodenough,et al.  Multisubunit assembly of an integral plasma membrane channel protein, gap junction connexin43, occurs after exit from the ER , 1993, Cell.